Veeva Systems Inc (VEEV): An IPO Loved by Hedge Funds

Initial Public Offerings (IPOs) can be an ideal way for investors to make a quick profit, especially if the company operates in a hot industry that garners a lot of market attention. For stocks that investors hold on to after their first day of trading, the opportunity could be even more interesting, as the shares potentially offer a fundamental growth story longer-term. We believe Veeva Systems Inc (NYSE:VEEV) could be one of those opportunities.

During the fourth quarter of 2013, many hedge funds bought new Class A shares of Veeva Systems, including Scott Fine and Peter Richards Empire Capital Management (who, with a 6% stake, is the sixth largest shareholder), Christopher Lord‘s Criterion Capital, Joe DiMenna‘s Zweig Dimenna Partners, and Brian Taylor‘s Pine River Capital Management.

Pine River Capital Management

Veeva Systems Inc (NYSE:VEEV) is a $4.4 billion market capitalization healthcare technology company that provides cloud-based software solutions to the biopharmaceutical (life sciences) industry for managing their content as well as relationships with customers and other external parties. Unlike larger peers salesforce.com, inc. (NYSE:CRM) or Oracle Corporation (NYSE:ORCL), Veeva is one of the early companies in the so-called Vertical Software-as-a-Service (SaaS) business, or providing cloud-based services tailored to the needs of specific, specialized markets, which some believe will be popular business models going forward. The company went public on October 16, 2013 by selling 15.0 million shares (including 3.3 million sold by existing owners) at an IPO price of $20, up significantly from an original range of $12-14 range. The stock closed that day at $37.16 and has been volatile, but is basically flat versus its first day’s closing price due to a combination of factors, including a high short interest (44% of float). Moreover, the company showed signs of slowing growth during its third quarter earnings release in early December (reporting year-over-year growth in revenue/billings was 95%/47%, versus 116%/75% in the prior quarter) and news of a lost high-profile client (Genentech).

Veeva Systems Inc (NYSE:VEEV)’s premium valuation reflects its high growth status, with a forward price / revenue and EV/EBITDA multiples of 17.7X (versus 3.6X for its peer group of healthcare technology companies) and 77.8X (versus 16.5X for peers), respectively. Interestingly, despite its growth, the company is profitable (a trait it had maintained even before going public, unlike other pre-IPO healthcare stocks), with margins much higher than the peer group median.

Longer-term, there will always be demand for Veeva Systems’s productivity and compliance solutions by the life sciences industry, which is under pressure to cut costs amid the expiration of patents on brand-name blockbuster drugs while navigating an increasingly complex and global regulatory environment. Hedge funds making a directional bet on the continuation of this secular industry trend could be gaining the appropriate exposure through Veeva Systems Inc (NYSE:VEEV), despite its lofty valuation.

Disclosure: none

Recommended Reading:

Ken Griffin and Citadel Are Bullish on Veeva Systems Inc (VEEV)

Empire Capital Management Adds Veeva Systems Inc (VEEV) to Its Equity Portfolio

Activist Investors are Betting on Allscripts Healthcare Solutions Inc. (MDRX)

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!